The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 20, 2017

Filed:

Aug. 26, 2015
Applicants:

Rutgers, the State University of New Jersey, New Brunswick, NJ (US);

Georgetown University, Washington, DC (US);

Inventors:

Siang-Yo Lin, East Brunswick, NJ (US);

Joseph R. Bertino, Branford, CT (US);

Chen-Yong Lin, Falls Church, VA (US);

Assignees:

RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, New Brunswick, NJ (US);

GEORGETOWN UNIVERSITY, Washington, DC (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); A61K 31/704 (2006.01); A61K 31/454 (2006.01); A61K 45/06 (2006.01); A61K 47/48 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/704 (2013.01); A61K 31/454 (2013.01); A61K 39/395 (2013.01); A61K 45/06 (2013.01); A61K 47/48384 (2013.01); A61K 47/48646 (2013.01); C07K 16/30 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01);
Abstract

The present invention relates to matriptase antibodies and immunoconjugates of matriptase antibodies with cytotoxic agents and the use thereof for killing or inhibiting the growth of matriptase-expressing cancer cells, such as those of multiple myeloma and breast cancers. In particular, immunoconjugates comprising a matriptase monoclonal antibody and anticancer agents such as doxorubicin (DOX) are introduced, which are equipotent to anticancer agents used in free form but exhibit significantly reduced cardiotoxicity and almost no adverse effects on normal bone marrow-derived mesenchymal stromal cells that do not express matriptase. The present invention also provides compositions comprising these new immunoconjugates and use of them for treatment of malignancies comprising cells that express matriptase. In addition, administration of a matriptase antibody or immunoconjugates of a matriptase antibody and a cytotoxic agent in combination with administration of an immunomodulatory agent, such as thalidomide or an analog thereof, provides a more effective treatment of these cancers.


Find Patent Forward Citations

Loading…